Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...
In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to include new pharmacodynamic data in Section 12.2. The ...
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share... MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX ...
In a report released yesterday, Andrew Tsai from Jefferies reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $40.00. The company’s shares ...
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years
Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) share price is up 57% in the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback